Literature DB >> 14743889

Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma.

C J Buskens1, A Ristimäki, G J A Offerhaus, D J Richel, J J B van Lanschot.   

Abstract

BACKGROUND: Various studies suggest that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) are promising anticancer agents. Epidemiological studies have found that long-term use of NSAIDs is associated with a reduced incidence of colorectal, gastric and oesophageal cancers, while experimental and clinical studies have demonstrated that treatment with NSAIDs causes a statistically significant reduction in both the number and the size of polyps in familial adenomatous polyposis (FAP) patients.
METHODS: In this review, the mechanisms by which NSAIDs exert their chemopreventive and antineoplastic effects are described.
RESULTS: Although the precise anticancer actions of NSAIDs are not fully explained, they probably involve inhibition of cyclooxygenase (COX), which is the rate-limiting enzyme in the conversion of arachidonic acid to prostaglandins. Two isoforms of this enzyme (COX-1 and COX-2) have been identified. COX-1 is constitutively expressed and considered to be a housekeeping gene, while COX-2 is not usually detectable in normal tissues, but can be readily induced in processes like inflammation, reproduction and carcinogenesis. The mechanisms by which COX-2 is thought to be involved in the carcinogenesis include resisting apoptosis, increasing cell proliferation, stimulating angiogenesis and modulating the invasive properties of cancer cells.
CONCLUSION: This report reviews the mechanisms by which COX-2 can contribute to carcinogenesis, its role in prognosis, and the possible place of selective COX-2 inhibitors in the prevention and treatment of gastrointestinal malignancies, focusing particularly on oesophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14743889     DOI: 10.1080/00855920310002753

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  8 in total

Review 1.  Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

Authors:  Panagiotis Tsibouris; Erasmia Vlachou; Peter Edward Thomas Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

2.  Altered membrane free unsaturated fatty acid composition in human colorectal cancer tissue.

Authors:  Barbara Szachowicz-Petelska; Stanisław Sulkowski; Zbigniew Artur Figaszewski
Journal:  Mol Cell Biochem       Date:  2006-07-21       Impact factor: 3.396

3.  Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Authors:  Hidekazu Kuramochi; Daniel Vallböhmer; Kazumi Uchida; Sylke Schneider; Nahid Hamoui; Daisuke Shimizu; Parakrama T Chandrasoma; Tom R DeMeester; Kathleen D Danenberg; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

4.  Mechano-transcription of COX-2 is a common response to lumen dilation of the rat gastrointestinal tract.

Authors:  Y-M Lin; F Li; X-Z Shi
Journal:  Neurogastroenterol Motil       Date:  2012-04-10       Impact factor: 3.598

5.  COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease.

Authors:  Georg Lurje; Daniel Vallbohmer; Peter H Collet; Huan Xi; Stephan E Baldus; Jan Brabender; Ralf Metzger; Michaela Heitmann; Susanne Neiss; Ute Drebber; Arnulf H Holscher; Paul M Schneider
Journal:  J Gastrointest Surg       Date:  2007-07-10       Impact factor: 3.452

6.  Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosphotransferase, of human mesangial cells.

Authors:  Alexandros Basilios Tsoupras; Elizabeth Fragopoulou; Tzortzis Nomikos; Christos Iatrou; Smaragdi Antonopoulou; Constantinos Alexandros Demopoulos
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

7.  Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway.

Authors:  Runchen Miao; Xinsen Xu; Zhixin Wang; Sushun Liu; Kai Qu; Wei Chen; Chang Liu
Journal:  Mol Med Rep       Date:  2017-12-22       Impact factor: 2.952

8.  circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD-L1 through NF-κB pathway.

Authors:  Fan Wu; Guoqiang Sun; Wubin Zheng; Weiwei Tang; Ye Cheng; LiangLiang Wu; Xiao Li; Jing Tao; Shijie Ma; Hongyong Cao
Journal:  J Clin Lab Anal       Date:  2021-10-22       Impact factor: 2.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.